Reapplix ‘Focused Exclusively’ On US Wound Patch Launch After Securing Reimbursement

Reapplix’s CEO tells Medtech Insight the Danish group now has the funds to launch its biological wound healing patch in the US for treating patients with diabetic foot ulcers.

Foot_Ulcer
Reapplix’s 3CPatch System repairs hard-to-heal diabetic foot ulcers. • Source: Shutterstock

Reapplix APS has postponed indefinitely plans to roll out its proprietary biological wound-healing patch in Europe for treating patients with diabetic foot ulcers due to uncertainty over product reimbursement there. It will instead focus exclusively on launching its 3CPatch in the US where it has its reimbursement rate and coding recently confirmed, the Danish group’s CEO said in an interview.

Reapplix’s path to commercializing its 3CPatch in the US opened up when the group received Medicare reimbursement coding instructions from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Diabetic Care

More from Device Area